Background: Previous studies have shown that industry funded trials are associated with pro-industry conclusions and publication bias. Less is known about the role of industry funders and their influence on trial conclusions and time to publication.
Introduction
Industry plays an important role in funding and conducting clinical trials in oncology. The growing scale and cost of oncology trials are important factors that favor industry collaboration. Approximately 40% of industry research and development is now devoted to oncology drugs [1] . Our previous study showed that industry funded 66% of the published phase III oncology trials [2] . While industry's investment in research has spawned breakthroughs and innovations in oncology, these investments have also fueled concerns that industry-funded clinical trials are more likely to have pro-industry conclusions [3, 4] , potentially distorting the evidence base to favor more expensive products.
Industry funding that goes to academic researchers often comes with conditions that allow sponsors to collect data, prepare, or even delay publication. Bias may be introduced or amplified when sponsors are directly involved in clinical trials because commercial interests can exert influence at multiple stages, such as analyzing, writing and publication. It may shape the resulting article and delay or even prevent publication of negative trials. Although the impact of industry funding on primary research has received considerable attention in medical oncology, less is known about the role of the funders and its influence on the conclusions of trials [5] .
Rapid publication of trials, regardless of whether their results are positive or negative, is essential to yield maximal benefits for public health, facilitate scientific progress, and enable clinicians and other stakeholders to make decisions. By preferential and/or more rapid publication of positive results, reported outcomes may be distorted and provide false impressions about the efficacy of a given therapeutic innovation. Previous studies have shown that there is a time lag in the publication of negative findings [6, 7] . Whether the presence of role of industry funders influences the association of trial results with time to publication of oncology trials is unknown.
The CONSORT statement requires authors to describe in detail the role of the funders [8] . Most scientific journals also require authors to provide details of the funding source [9] . This movement towards transparency provides an opportunity to examine the extent to which funders are involved in the design, data collection, data analysis and manuscript preparation of clinical trials.
The present study aims to evaluate the role of industry funders of recent randomized controlled trials (RCTs) in oncology published in high-impact journals and to identify whether role of industry funders is associated with trial conclusions and time of publication.
Methods

Identification of study cohort
We searched MEDLINE via PubMed to identify RCTs for cancer published between January 2014 and December 2016 in Lancet, Lancet Oncology, JAMA, JAMA Oncology, New England Journal of Medicine (NEJM) and Journal of Clinical Oncology (JCO). We selected articles published in these journals because they are high-impact journals that published majority of breakthrough oncology RCTs and provide information about the role of industry funders. We searched MEDLINE using the Cochrane Highly Sensitive Search Strategy to identify RCTs (search strategy is provided in supplementary material, available at Annals of Oncology online). A hand search of the journals' tables of contents was conducted to supplement previous search results.
We included phase II or III oncology RCTs evaluating systemic therapy with at least partial funding from industry. We excluded letters, news or editorials, reviews and meta-analysis, observational or retrospective studies, nonrandomized studies, or nonprimary reports, noncancer trials, and surgery, radiation, screening, diagnostic, behavior or dietary trials. Trials comparing different doses or timing of the same medication were also excluded.
Data abstraction and scoring
For trials published in Lancet, Lancet Oncology, JAMA and JAMA Oncology, authors are required to report the role of the funder. We extracted the information of the role of the funder in trial design, data collection, data analysis, data interpretation and manuscript writing from these specific sections. For trials published in NEJM, the role of the funder was determined from the methods section of the report. For trials published in JCO, authors are required to report their specific contributions under the headings 'Conception and design', 'Collection and assembly of data', 'Data analysis and interpretation' and 'Manuscript writing'. This information was combined with the affiliations of the authors to determine the role of the industry funders. We also screened the full methods section and appendices of reports to obtain all related information. The commercial funder's review of a manuscript before submission was not considered as having a role in manuscript writing. For trial design, data collection, data analysis and data interpretation, we further categorized trials as having a higher level of industry involvement if there were statements such as: 'Trial designed by funder', 'Data collected by funder', 'Data analyzed by funder', 'Data interpreted by funder' or similar statements. These categories indicated that industry funders had a leading role in these aspects. For manuscript writing, we defined a higher level of industry involvement as 'initial draft prepared by funder' if it is stated explicitly that industry funders prepared the initial draft. We used this category because in all trials academic authors are required to be involved in writing the final manuscript, but the initial draft will usually set the tone for the final report.
Two review authors (FL and SZ) examined independently titles and abstracts to exclude irrelevant reports, examined full-text articles to determine eligibility and extracted the role of the industry funders using standardized forms. We used the k coefficient to determine degree of agreement between reviewers. Disagreements were discussed to reach consensus.
Two investigators (JZ and YZ) who were blinded to information about the role of funders evaluated each RCT according to the conclusion stated in the abstract on a five-point scale of positivity (i.e. extent to which the authors favored experimental intervention) used previously [3, 10] ; previous investigations have shown that physicians frequently read only the abstracts when reviewing the medical literature [11] . Authors' conclusions were classified as highly positive (1 point: completely positive opinion without any negative consideration), positive (2 point: general positive opinion with minor negative considerations), neutral (3 point: neutral or inconclusive opinion), negative (4 point: general negative opinion, with minor positive considerations), or highly negative (5 point: completely negative opinion without any positive consideration).
For all RCTs, we defined the time to publication (in days) as time from the primary data cutoff date (if not available, the data lock date was used) to the date of primary publication. For publications available online ahead of print, we adopted the earlier online access date. If only the month of data cutoff was reported, the middle of the month was used. When the data cut-off date was not reported, ClinicalTrials.gov was searched to identify this information. Studies without information on the primary cutoff date were excluded from the time-to-publication analysis. The following information was also extracted: journals, treatment regimen, control type, primary outcome, study results, trials phase, sample size and statistical design.
Statistical analyses
Continuous variables were described with median and range, and categorical variables were described with counts and proportions. The conclusion scores between trials with or without role of industry funders were compared using the Mann-Whitney U test. Multivariable ordinal logistic regression was used to examine whether the role of industry funders could predict more favorable conclusions by authors after adjustment for seven pre-specified study characteristics: journal type (general medical journals versus oncology journals), statistical design (superiority versus noninferiority or equivalence), sample size (interquartile), type of primary outcome (overall survival versus others), type of control (placebo/best supportive care versus active control), trial phase (phase II versus phase III), and study results (positive versus negative). Positive results were defined as achievement of statistical significance for the primary outcome and negative results were defined as failure to achieve statistical significance for the primary outcome. Odds ratios (ORs) were used to describe the association between conclusion score and possible predictive factors. OR > 1 indicates higher odds of more positive conclusion. The assumption of proportionality was checked by test of parallel lines, which was generally satisfied (P >0.05).
The median time to publication for trials with positive or negative results was estimated by Kaplan-Meier methods and compared to use of log-rank test. Multivariable Cox proportional-hazards were used to explore whether the pre-specified seven study characteristics were associated with time to publication. Particularly, we tested the interaction between trials results (positive versus negative) and role of industry funders (with versus without) by including an interaction term (primary outcome results Ârole of industry funders) in our Cox model. Conditional on the finding of a statistically significant interaction (P < 0.05), we further evaluated the association of study results with rapidity of publication separately in subgroups of trials with or without a role of industry funders, and the association of the role of industry funders with rapidity of publication in subgroups of trials with positive or negative results.
Data analyses were conducted using SPSS software (version 21; IBM, Armonk, NY). All statistical tests were two sided, and statistical significance was defined as P < 0.05. No corrections were made for multiple testing.
Results
After screening of 1945 initially identified articles, 255 trials were eligible and included in the analysis. A full list of all included trials is provided in supplementary Table S1 , available at Annals of Oncology online. The screening process and reasons for exclusion are shown in supplementary Figure S1 , available at Annals of Oncology online.
The characteristics of the included trials are detailed in Table 1 . The median number of patients enrolled was 477 (range 58-8381).The majority of RCTs were published in Lancet Oncology (38.0%) and JCO (32.5%). Among these trials, 87.1% were superiority design, 60.9% reported positive results and 75.2% used an active control. Overall survival was the primary end point in 31.8% of trials. Agreement between reviewers for grading of trial conclusions, role of industry funders determination and extraction of baseline characteristics was 0.89 (95% CI 0.84-0.93), 0.91 (95% CI 0.86-0.95) and 0.88 (95% CI 0.83-0.93), respectively. Industry funders had a role in at least one aspect in 186 (72.9%) trials, and in 118 (46.3%) trials, the funders had a role in all five aspects. Industry funders had a role in trial design in 179 (70.2%) trials, and 15 (5.9%) trials had a higher level of industry involvement. Industry funders had a role in data collection in 160 (62.7%) trials and had a higher level of involvement in 50 (19.6%) trials. Industry funders had a role in in data analysis in 173 (67.8%) trials and had a higher level of involvement in 57 (22.4%) trials. For data interpretation, industry funders had a role in 135(52.9) trials. Industry funders had a role in manuscript writing in 168 (65.9%) trials, and had a higher level of involvement in 8 (3.1%) trials (Table 2 ).
For trials influenced by industry funders, the conclusions of authors stated in the abstracts were determined to be highly positive in 88 (47.3%) trials, highly negative in 24 (12.9%) trials, with a mean evaluation score of 2.16 (standard deviation, 1.42). For trials without industry influence, conclusions of authors were clarified as highly positive in 22 (31.9%) trials, highly negative in 16 (23.2%) trials, with a statistically significant (P ¼ 0.029) lower mean evaluation score of 2.59 (standard deviation, 1.57) (supplementary Table S2 , available at Annals of Oncology online). In the multivariable ordinal logistic regression analyses, trials with industry influence had 3.6 times (95% CI 2.0-6.6) higher odds of having lower conclusion score (lower score indicates more positive conclusion) than those without industry influence (Table 3) .
Time to publication can be determined for 236 trials. In multivariable Cox analyses, publication in general medical journals, positive results, larger sample size and any role of industry funders were statistically associated with more rapid publication (supplementary Table S3 , available at Annals of Oncology online). Significant interaction between study results and role of industry Authors' conclusions were classified on a 5-point scale (1, highly positive; 2, positive; 3, neutral; 4, negative; 5, highly negative) of positivity with respect to the authors' opinion about the experimental intervention. funders was detected (interaction P < 0.0001). In trials influenced by industry funders, trials with positive results were published significantly faster than trials with negative results (HR ¼ 4.3; 95% CI 2.7-6.7, P < 0.001), while for trials without industry influence, there was no significant difference in time to publication between trials with positive results and those with negative results (HR ¼ 1.07; 95% CI 0.57-1.99, P ¼ 0.84). Within the subgroup of trials with positive results, trials were published faster (HR ¼ 2.0, 95% CI 1.3-3.1; P ¼ 0.001) if influenced by industry funders, while for trials with negative results, influence by industry was associated with a nonsignificant trend to slower publication (HR ¼ 0.65, 95% CI 0.37-1.16, P ¼ 0.145) (Figure 1 ). Given the potential confounding by journal type, we undertook a sensitivity analysis in which the Cox models were adjusted for each journal instead of being classified as general medical journals or oncology journals. The results did not change significantly and were consistent with the present analysis.
Discussion
In this large sample of phase III oncology trials published recently in high impact journals, we demonstrated that pharmaceutical companies have been involved in the trial design, data collection, data analysis, data interpretation and manuscript preparation of industry funded clinical trials, with 72.9% trials reporting a role of the funder in at least one aspect and 46.3% in all aspects. Our analysis revealed that influence of the sponsor was associated with more positive conclusions. Furthermore, we also found that among industry-funded RCTs, there is delay in time to publication of negative trials compared with positive ones. This time lag is more striking in trials with industry influence, with positive trials published more than four times faster than negative ones, while there was no significant difference in time to publication of positive and negative trials if there was no detectable role of industry funders. Several reasons may contribute to the high prevalence of industry involvement in oncology RCTs. Firstly, trials are very expensive and academic centers involve the pharmaceutical industry to obtain funding. Secondly, industry may still rely on prestigious academic institutions to perform trials and to publish them in high impact journals. Thirdly, industry employs top-level research physicians to design and interpret drugs trials, and community physicians have become a reliable source of patients, which has reduced industry's dependence on academia.
It is reasonable for companies to be involved in trial design, since many RCTs may be registration trials, and study design and selection of control arms for these studies will be influenced by regulatory requirements for drug development. However, the involvement of industry in data collection, data interpretation, data analysis and manuscript writing is worrisome. In 57 (22.4%) trials, data were analyzed by the industry funders, so it is possible that academically affiliated authors may be only involved in the manuscript preparation after the completion of data analysis. A previous study [12] showed that for over one third of RCTs, reanalysis of individual patient data from previously published RCTs addressing the same hypothesis as that of the original RCT led to changes in findings. Appropriate research collaborations focusing on patient benefits should be fostered, taking advantage of the skills and knowledge of those in industry and academia. Academic researchers have an ethical obligation to submit creditable research results for publication. Researchers therefore should not enter into agreements that interfere with their access to data or their ability to analyze data independently, to prepare manuscripts, or to publish them. To do so, academic institutions and investigators should use ICMJE recommendations [13] to defend the academic freedom in negotiating clinical-trial agreements with industry. For medical journals, besides the requirement of disclosure of the role of industry funders, publication of protocols [14, 15] and sharing of clinical trial data [16] should be encouraged to provide a guardrail against possible bias in a clinical trial system in which industry involvement is common.
Two recent studies reported that neither industry-sponsored trials nor trials with industry collaboration were significantly associated with positive study results [5, 17] . Our study differed from these two studies may be due to the differences in evaluation of outcomes. These studies focused on trials results, which were classified as positive or negative on the basis of whether the primary outcome was met. However, we investigated the association between the role of industry funders and trial conclusions graded using a 5-score scale. The conclusion of trials with positive results may be interpreted negatively due to substantial toxicity of the experimental arm [18] . Conclusions of trials with a negative primary outcome may be interpreted positively based on positive subgroup analysis [2] , or important secondary outcomes [19] .
Our study found that there is a time lag in the publication of negative findings for trials with industry involvement. Timely publication of trials results, no matter whether they are positive or negative, can have a direct effect on clinical practice and policy. Many reasons could contribute to publication lag. For example, medical journals may intend to favor positive trials [7] and negative trials may had been submitted to several journals before they can get published. However, our results remained unchanged after adjustment for factors such as journal type, and for trials without industry influence, there was no significant difference in time to publication between positive and negative trials.
Our study has several limitations. First, the disclosure form indicating the role of industry funders varied among journals due to the difference in disclosure policies. Bias may be introduced when pooling data from different journals. Secondly, because our analyses were based on reported disclosure, we cannot ascertain that the role of industry funder was completely and accurately reported. Thirdly, our study only included articles that were published in a few high impact journals that may not reflect the entire body of oncology medical literature. However, most practice-changing and high quality phase III RCTs are published in these journals, which are also pioneers of the policy of requiring the disclosure of role of industry funders in RCTs to the public. Finally, given that for all the 186 trials with any role of industry funders, industry was involved in at least four of the 5 aspects in 170 (91.4%) trials, we cannot distinguish the effect of any specific type of involvement.
Conclusion
Our findings suggest that industry funders are intimately involved in all aspect of industry funded clinical trials, including trial design, data collection, data analyses, data interpretation and manuscript preparation. The influence of industry sponsors was associated with more favorable conclusions and more rapid publication of positive trials.
